Evaluation of Human Papillomavirus Antibodies and Risk of Subsequent Head and Neck Cancer
Author(s) -
Aimée R. Kreimer,
Mattias Johansson,
Tim Waterboer,
Rudolf Kaaks,
Jenny ChangClaude,
Dagmar Drogen,
Anne Tjønneland,
Kim Overvad,
J. Ramón Quirós,
Carlos A. González,
MaríaJosé Sánchez,
Nerea Larrañaga,
Carmen Navarro,
Aurelio Barricarte,
Ruth C. Travis,
KayTee Khaw,
Nicholas J. Wareham,
Antonia Trichopoulou,
Παγώνα Λάγιου,
Dimitrios Trichopoulos,
Petra H. Peeters,
Salvatore Panico,
Giovanna Masala,
Sara Grioni,
Rosario Tumino,
Paolo Vineis,
H. Bas BuenodeMesquita,
Göran Laurell,
Göran Hallmans,
Jonas Manjer,
Johanna Ekström,
Guri Skeie,
Eiliv Lund,
Elisabete Weiderpass,
Pietro Ferrari,
Graham Byrnes,
Isabelle Romieu,
Elio Ríboli,
Allan Hildesheim,
Heiner Boeing,
Michael Pawlita,
Paul Brennan
Publication year - 2013
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2012.47.2738
Subject(s) - medicine , head and neck cancer , cancer , odds ratio , oncology , larynx , confounding , prospective cohort study , proportional hazards model , cohort , cohort study , surgery
Human papillomavirus type 16 (HPV16) infection is causing an increasing number of oropharyngeal cancers in the United States and Europe. The aim of our study was to investigate whether HPV antibodies are associated with head and neck cancer risk when measured in prediagnostic sera.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom